POSTER SESSION I

ASTHMA

INFECTION

CARDIOVASCULAR DISEASE
	-Angina /Ischemia -Angioplasty -Arrhythmia -Atrial Fibrillation -Congestive Heart Failure/Heart Failure -Coronary Artery Disease -Hypercholesterolemia -Myocardial Infarction -Other -Thrombosis Including DVT

NEUROLOGICAL DISORDERS
	-Alzheimer’s Disease -Epilepsy -Migraine -Multiple Sclerosis -Other -Parkinson’s Disease -Sleep Disorders

ENDOCRINE DISORDER

RESPIRATORY DISORDERS

HEMATOLOGICAL DISORDERS

SKIN

HEALTH POLICY

SMOKING

HEALTH–Children’s

STROKE

HEALTH–Elderly

STENTS

HEALTH–Men’s

SURGERY

HEALTH–Women’s

» Poster Session II

ASTHMA

PAS1	HEALTH CARE UTILIZATION, COST AND MEDICATION USE AMONG PEDIATRIC ASTHMA PATIENTS Modi A, Iyer R, Lawrence L University of Louisiana at Monroe, Monroe, LA, USA
PAS2	IMPACT OF ANTI-INFLAMMATORY MEDICATION ON ASTHMA COSTS IN A PEDIATRIC POPULATION Sapra SJ¹, Martin BC², Dorfman JH³ ¹ University of California, San Francisco, CA, USA; ² University of Arkansas for Medical Sciences, Little Rock, AR, USA; ³ University of Georgia, Athens, GA, USA
PAS3	A COMPARISON OF ASTHMA MEDICATION USE IN PUBLICLY VERSUS PRIVATELY INSURED CHILDREN WITH ASTHMA Ungar WJ¹, Kozyrskyj A², Paterson M³, Mamdani M³, Gunraj N³, Ahmad F⁴ ¹ The Hospital for Sick Children, Toronto, ON, Canada; ² Manitoba Centre for Health Policy, Winnipeg, MB, Canada; ³ Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; ⁴ Brogan Inc, Ottawa, ON, Canada
PAS4	PATTERNS OF PHARMACOTHERAPY UTILIZATION AMONG CHILDREN AND ADOLESCENTS WITH MULTIPLE ASTHMA-RELATED MORBID EVENTS ENROLLED IN A MEDICAID PROGRAM D'Souza AO, Smith M, Roy AN West Virginia University, Morgantown, WV, USA
PAS5	DRUG COST ANALYSIS OF TREATMENT FOR ASTHMA OUTPATIENTS IN TAIWAN Lu CH¹, Tarn YH² ¹ National Defense Medical Center, Taipei, Taipei, Taiwan; ² Taipei City Hospital, Taipei, Taiwan
PAS6	IMPACT OF ASTHMA KNOWLEDGE ON HEALTH OUTCOMES IN PEDIATRIC PATIENTS Suksomboon N, Montakantikul P Mahidol University, Payathai, Bangkok, Thailand
PAS7	DIRECT AND INDIRECT COST OF ASTHMA IN AN EMPLOYER POPULATION Atherly A, Nurmagambetov T, Williams S Centers for Disease Control and Prevention, Atlanta, GA, USA
PAS8	A DYAD APPROACH TO QUALITY OF LIFE MEASUREMENT IN CHILDREN WITH ASTHMA Mirabelli C, Cousins M, Boydell K, Ungar WJ The Hospital for Sick Children, Toronto, ON, Canada
PAS9	CHOOSING AMONG DIFFERENT TYPES OF MATCHING TECHNIQUES Baser O Medstat, Inc, Ann Arbor, MI, USA

CARDIOVASCULAR DISEASE-Angina /Ischemia

PCV1	COMPARISON OF ALTERNATIVE STRATEGIES FOR THE DIAGNOSIS OF ACUTE CARDIAC ISCHEMIA IN EMERGENCY DEPARTMENTS: STANDARD OF CARE VERSUS BMIPP Wu EQ¹, Birnbaum H¹, Cremieux P¹, Carpenter S¹, Borys N², Babich JW², Setnik G³ ¹ Analysis Group, Inc, Boston, MA, USA; ² Molecular Insight Pharmaceuticals, Cambridge, MA, USA; ³ Mt Auburn Hospital, Cambridge, MA, USA
PCV2	ACUTE CORONARY SYNDROMES: ONE YEAR COSTS AND OUTCOMES Taylor M¹, Scuffham P², McCollam PL³, Newby D⁴ ¹ York Health Economics Consortium, Heslington, York, United Kingdom; ² School of Population Health, Herston, Queensland, Australia; ³ Eli Lilly and Company, Indianapolis, IN, USA; ⁴ University of Edinburgh, Edinburgh, East Lothian, United Kingdom
PCV3	UTILIZATION OF RECOMMENDED DRUG THERAPY IN ACUTE CORONARY SYNDROME Patel CK, McCollam PL, Bae JP Eli Lilly and Company, Indianapolis, IN, USA
PCV4	LONG-TERM THIENOPYRIDINE THERAPY IN ACS PATIENTS RESIDING IN THE UNITED KINGDOM McCollam PL¹, Lage MJ², Bowman L¹ ¹ Eli Lilly and Company, Indianapolis, IN, USA; ² HealthMetrics Outcomes Research, Groton, CT, USA
PCV5	POTENTIAL COST SAVINGS FROM ACUTE CORONARY SYNDROME TREATMENT IMPROVEMENTS Klein RW¹, Ohsfeldt RL², Smolen LJ¹, McCollam PL³ ¹ Medical Decision Modeling Inc, Indianapolis, IN, USA; ² The University of Iowa College of Public Health, Iowa City, IA, USA; ³ Eli Lilly and Company, Indianapolis, IN, USA

CARDIOVASCULAR DISEASE-Angioplasty

PCV6

LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (CREDO TRIAL): A FOUR-EUROPEAN COUNTRY ANALYSIS
Weintraub WS¹, Bouin O², Veledar E¹, Gabriel S²
¹ Emory University, Atlanta, GA, USA; ² Sanofi-Aventis, Bagneux, France

CARDIOVASCULAR DISEASE-Arrhythmia

PCV7

HEALTH CARE RESOURCE UTILIZATION AND COST OF ATRIAL FLUTTER PATIENTS
Pelletier E¹, Reyes CM¹, Hernandez J¹, Lee BK²
¹ Boston Scientific Corporation, San Jose, CA, USA; ² University of California San Francisco, San Francisco, CA, USA

CARDIOVASCULAR DISEASE-Atrial Fibrillation

PCV8	TOTAL HEALTH CARE COSTS OF PATIENTS WITH CHRONIC NON-VALVULAR ATRIAL FIBRILLATION BEFORE AND AFTER TIA, ISCHEMIC STROKE OR MAJOR BLEED Stephenson JJ¹, Fernandes J¹, Beaulieu JF¹, Del Aguila MA¹, Hauch O², Kim J², Boccuzzi SJ¹ ¹ Aetna Health Information Solutions, Blue Bell, PA, USA; ² AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
PCV9	COST-EFFECTIVENESS OF AMIODARONE TO PREVENT ATRIAL FIBRILLATION AFTER CARDIAC SURGERY Reddy P¹, Gao X², Burrell A³, Boci K², Bouin O⁴ ¹ Abt Associates Inc, Lexington, MA, USA; ² Abt Associates Inc, Bethesda, MD, USA; ³ Sanofi-Aventis, Bridgewater, NJ, USA; ⁴ Sanofi-Aventis, Bagneux, France
PCV10	RACE AND GENDER COST DIFFERENCES ASSOCIATED WITH COMORBID ATRIAL FIBRILLATION IN THE HOSPITAL SETTING Coyne KS¹, Paramore LC¹, Grandy S², Mercader M³, Reynolds M⁴, Zimetbaum PJ⁴ ¹ MEDTAP International, Inc, Bethesda, MD, USA; ² AstraZeneca, LP, Wilmington, DE, USA; ³ George Washington University, Washington, DC, USA; ⁴ Beth Israel Deaconess Medical Center, Boston, MA, USA
PCV11	QUALITY OF ANTICOAGULATION CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION MANAGED IN ROUTINE MEDICAL CARE IN THE UNITED STATES Ansell JE¹, Caro JJ², Proskorovsky I³, Lordan N², Salas M², Hauch O⁴, Wygant G⁴, Hollowell J⁵, Bjorholt I⁶ ¹ Boston Medical - Boston University, Boston, MA, USA; ² Caro Research, Concord, MA, USA; ³ Caro Research Institute, Dorval, QC, Canada; ⁴ AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA; ⁵ AstraZeneca R&D Mölndal, Mölndal, Sweden; ⁶ Nordic Health Economics Research AB, Hovas, Sweden
PCV12	DATA CAPTURE VIA INTERACTIVE VOICE RESPONSE SYSTEM IN A NATIONAL STUDY OF ANTICOAGULATION MANAGEMENT Payne K¹, Lordan N², Caro JJ², O'Brien J² ¹ Caro Research Institute, Dorval, QC, Canada; ² Caro Research Institute, Concord, MA, USA

CARDIOVASCULAR DISEASE-Congestive Heart Failure / Heart Failure

PCV13	COST-EFFECTIVENESS EVALUATION OF EPLERENONE IN PATIENTS WITH HEART FAILURE FOLLOWING AMI IN GERMANY Kvasz M¹, Zhang Z², Lenz C³, Mundhenke M³, Weintraub WS² ¹ Pfizer Inc, New York, NY, USA; ² Emory University, Atlanta, GA, USA; ³ Pfizer Pharma GmbH, Karlsruhe, Germany
PCV14	MODELING THE ECONOMIC CONSEQUENCES OF CARDIAC RESYNCHRONIZATION THERAPY IN THE UK Caro JJ, Drummond TL Caro Research, Concord, MA, USA
PCV15	POTENTIAL MEDICAL COST OFFSETS OF TREATMENT WITH ISOSRBIDE DINITRATE PLUS HYDRALAZINE IN AFRICAN AMERICANS WITH HEART FAILURE Becker R¹, Klingman D² ¹ ValueMedics Research, Chicago, IL, USA; ² ValueMedics, Falls Church, VA, USA
PCV16	INCREMENTAL EFFECTS OF CONCURRENT PHARMACOTHERAPEUTIC REGIMENS FOR HEART FAILURE ON HOSPITALIZATIONS AND COSTS Skrepnek GH¹, Abarca J¹, Malone DC¹, Armstrong EP¹, Shirazi FM², Woosley RL² ¹ University of Arizona College of Pharmacy, Tucson, AZ, USA; ² University of Arizona College of Medicine, Tucson, AZ, USA
PCV17	CAREMARK CAREPATTERNS®HEART FAILURE HOME MONITORING PROGRAM IMPROVES PARTICIPANTS’ HOME MONITORING COMPLIANCE Fensterheim LE¹, Duff D², Sellers Y², Hu L¹, Stine N¹ ¹ Caremark Inc, Northbrook, IL, USA; ² Caremark Inc, San Antonio, TX, USA
PCV18	USE OF ß-BLOCKERS FOR TREATING HEART FAILURE AMONG THE ELDERLY IN BRITISH COLUMBIA, CANADA, 1993-2001 Levy A¹, Johnston K¹, Gustafson P¹, Palepu A¹, Reid R², Brophy J³, Mcgrail K¹ ¹ University of British Columbia, Vancouver, BC, Canada; ² Group Health Permanente, Seattle, WA, USA; ³ McGill University, Montreal, QC, Canada
PCV19	TRENDS IN PHARMACY USE AMONG VETERANS WITH CHRONIC HEART FAILURE (1999-2002) Johnson ML, Henderson L, Petersen N, Espadas D, Yu H, Campbell J, Moffett M, Deswal A Baylor College of Medicine, Houston, TX, USA
PCV20	DECREASING HOSPITALIZATIONS FOR HEART FAILURE IN BRITISH COLUMBIA, CANADA, 1993-2001 Levy A¹, Johnston K¹, Gustafson P¹, Palepu A¹, Reid R², Brophy J³, Mcgrail K¹ ¹ University of British Columbia, Vancouver, BC, Canada; ² Group Health Permanente, Seattle, WA, USA; ³ McGill University, Montreal, QC, Canada
PCV21	EFFECTIVENESS OF CLINICAL PATHWAYS FOR INPATIENT HEARTH FAILURE TREATMENT: RESULTS OF A MULTICENTER CONTROLLED TRIAL Panella M¹, Marchisio S², Barbieri A², Demarchi ML¹ ¹ University of Eastern Piedmont, Novara, Italy; ² Saint Andrew Hospital, Vercelli, Italy

CARDIOVASCULAR DISEASE-Coronary Artery Disease

PCV22	HEALTH AND ECONOMIC BURDEN OF POOR MEDICATION ADHERENCE IN THE UNITED STATES Thompson D¹, Wang Y², Sarocco P³, Neumann P⁴, Weinstein M² ¹ Innovus Research, Inc, Medford, MA, USA; ² Harvard School of Public Health & Innovus Research, Inc, Boston, MA, USA; ³ Sanofi-Aventis US Pharma, Bridgewater, NJ, USA; ⁴ Harvard University, Boston, MA, USA
PCV23	EVALUATING THE DIAGNOSTIC VALIDITY OF ADMINISTRATIVE CLAIMS DATA FOR COMMON CHRONIC DISEASES Yu YF, Bullano M, Willey VJ HealthCore, Inc, Wilmington, DE, USA

CARDIOVASCULAR DISEASE-Hypercholesterolemia

PCV24	WHAT IS THE RELEVANCE OF AGE GROUPS IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS? A COST - UTILITY ANALYSIS IN MEXICO Mould Quevedo JF, Contreras I, Salinas - Escudero G, Garduño J Social Security Mexican Institute, México D.F, México D.F, Mexico
PCV25	COST EFFECTIVENESS OF ATORVASTATIN (LIPITOR) AS SINGLE THERAPY AND DUAL THERAPY WITH EZETIMIBE (ZETIA) Bui T, Harrison DL University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
PCV26	COST-EFFECTIVENESS OF EZETIMIBE CO- ADMINISTRATION IN CHD PATIENTS NOT AT GOAL WITH CURRENT STATIN THERAPY IN HONG KONG Lee VW¹, Chan WK², Alemao E³, Yin D³, Cook JR⁴, Lee BS⁵, Chong AC², Tomlinson B¹, Wong JC⁵, Lee KKC¹ ¹ The Chinese University of Hong Kong, Shatin, Hong Kong, China; ² United Christian Hospital, Kwun Tong, Hong Kong, China; ³ Merck & Co., Inc, Whitehouse Station, NJ, USA; ⁴ Merck & Co., Inc, Blue Bell, PA, USA; ⁵ Prince of Wales Hospital, Shatin, Hong Kong, China
PCV27	AN ECONOMIC ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED TO USUAL CARE WITH STATIN MONOTHERAPY Nag SS¹, Sajjan SG¹, Kamal Bahl S¹, Cook JR², Soffer J³, Rajagopal G², John A⁴, Heithoff K⁴, Markson LE¹, Alexander CM¹ ¹ Merck & Co., Inc, West Point, PA, USA; ² Merck & Co., Inc, Blue Bell, PA, USA; ³ Merck & Co., Inc, Upper Gwynedd, PA, USA; ⁴ Schering-Plough Pharmaceuticals, Kenilworth, NJ, USA
PCV28	COST- UTILITY ANALYSIS FOR STATINS IN MEXICO Mould Quevedo JF, Contreras I, Nevarez A, García - Contreras F, Constantino - Casas P, Garduño J Social Security Mexican Institute, México D.F, México D.F, Mexico
PCV29	PREDICTORS OF COMPLIANCE AND PERSISTENCE TO STATIN THERAPY AMONG TEXAS MEDICAID PATIENTS Dastani H¹, Shepherd M¹, Sasane R² ¹ University of Texas at Austin, Austin, TX, USA; ² AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
PCV30	COMPLIANCE WITH STATIN TREATMENT: THE EFFECT OF SWITCHING TO ANOTHER STATIN AFTER TREATMENT INITIATION Thiebaud P¹, Nichol MB¹, Patel BV² ¹ University of Southern California, Los Angeles, CA, USA; ² MedImpact Healthcare Systems, Inc, San Diego, CA, USA
PCV31	DOES PLAN DESIGN AFFECT THERAPY ADHERENCE FOR CHRONIC CONDITIONS? Matlin OS, Marks AS, Xiao Q Caremark Inc, Northbrook, IL, USA
PCV32	EVALUATION OF FACTORS RELATED TO DIAGNOSIS OF HYPERLIPIDEMIA: THE ROLE OF DIRECT-TO-CONSUMER ADVERTISING EXPENDITURES, HEALTH INSURANCE COVERAGE, AGE AND GENDER Nair R, Shepherd M, Barner J, Lawson K, Wilson J, Warner D University of Texas, Austin, TX, USA
PCV33	MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY Dastani H¹, Shepherd M¹, Sasane R² ¹ University of Texas, Austin, TX, USA; ² AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
PCV34	EFFECT OF CO-PAYMENT ON THE INITIATION OF STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION Ye X¹, St.Peter WL¹, Gross CR¹, Xuan J² ¹ University of Minnesota, Minneapolis, MN, USA; ² Pfizer, New York, NY, USA
PCV35	EFFECT OF CLINICAL PHARMACIST INTERVENTION ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) OUTCOMES IN AN AMBULATORY SETTING Guy-Alfandary S, Lavi S, Raz M, Triki N Maccabi Healthcare Services, Rishon Le Zion, Israel
PCV36	CHOLESTEROL GOAL ATTAINMENT IN DYSLIPIDEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE Van Ganse E¹, Souchet T², Laforest L³, Moulin P⁴, Bertrand M⁵, Le Jeunne P⁶, Chretin S³, De Pouvourville G⁷ ¹ CHU Lyon, Pierre Bénite, France; ² Merck Sharp & Dohme - Chibret, Paris, France; ³ Pharmacoepidemiology, CHU-Lyon, Pierre Bénite, France; ⁴ Hopital Louis Pradel, Lyon, France; ⁵ CHU - Lille, Lambersart, France; ⁶ Thales, Boulogne Billancourt, France; ⁷ INSERM U 537, Le Kremlin-Bicêtre, France
PCV37	PREDICTING STATIN COMPLIANCE IN NEW STARTERS WITH PHARMACY CLAIMS Thiebaud P¹, Nichol MB², Patel BV³ ¹ University of Southern California, Los Angeles, CA, USA; ² University of Southern California, School of Pharmacy, Los Angeles, CA, USA; ³ MedImpact Healthcare Systems, Inc, San Diego, CA, USA

CARDIOVASCULAR DISEASE-Hypertension

PCV38	A COMPARISON OF THE ELIXHAUSER AND CHARLSON INDICES TO CONTROL FOR CONFOUNDING IN HEALTH OUTCOMES STUDIES Farley J University of Minnesota, Minneapolis, MN, USA
PCV39	WITHDRAWN
PCV40	PHARMACOECONOMIC EVALUATION OF ANTIHYPERTENSIVE THERAPY IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL , SAGAMU, OGUN SATATE, NIGERIA Suleiman IA¹, Lumor HA² ¹ University of Lagos, Lagos, Nigeria; ² Olabisi Onabanjo University Ago Iwoye, Sagamu Campus, Sagamu, Nigeria
PCV41	PATIENT EDUCATION AND ADHERENCE AND HYPERTENSION CONTROL IN TWO ACADEMIC MEDICAL CENTER PRIMARY CARE PRACTICES Crawford A, Roco C, Riggio J, Valko G, Goldfarb N, Nash DB Jefferson Medical College, Philadelphia, PA, USA
PCV42	ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS RELATED TO COPAYMENT LEVEL Taira DA¹, Davis JW¹, Wong KS², Frech F², Chung RS¹ ¹ Hawaii Medical Service Association (BCBS of Hawaii), Honolulu, HI, USA; ² Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
PCV43	INSURANCE COVERAGE AND AMBULATORY CARE OF HYPERTENSION FOR THE NEAR ELDERLY Raofi S¹, Shinogle J² ¹ National Center for Health Statistics, Hyattsville, MD, USA; ² Centers for Disease Control and Prevention, Hyattsville, MD, USA
PCV44	PHYSICAL INACTIVITY IS ASSOCIATED WITH INCREASED HEALTH CARE USE AND EXPENDITURES IN INDIVIDUALS WITH HYPERTENSION Iyer R, Modi A University of Louisiana at Monroe, Monroe, LA, USA
PCV45	ANTIHYPERTENSIVE THERAPY AFTER ALLHAT: ARE MORE PATIENTS STARTING WITH DIURETICS? Petrilla AA¹, Chapman RH¹, Lidsky L², Rucker M², Ollendorf DA², Benner JS¹ ¹ ValueMedics Research, LLC, Arlington, VA, USA; ² PharMetrics, Inc, Watertown, MA, USA
PCV46	USE OF NON-US SUPPLIED PHARMACEUTICALS IN THE TREATMENT OF HYPERTENSION IN A LATINO POPULATION IN LOS ANGELES COUNTY, CA, USA Wang SM, Bonnet PO, Wu J, Johnson KA University of Southern California, Los Angeles, CA, USA
PCV47	USE OF ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS NEWLY DIAGNOSED WITH HYPERTENSION Vincze G¹, Barner J² ¹ Novartis Pharma AG, Basel, Switzerland; ² University of Texas, Austin, TX, USA
PCV48	ASSESSMENT OF THE VALIDITY OF TWO CLAIMS-BASED ALGORITHMS IN IDENTIFYING HYPERTENSIVE PATIENTS Bullano M¹, Kamat S¹, Barlas S², Willey VJ¹, Makin C¹, Watson DJ², Brenneman SK³ ¹ HealthCore, Inc, Wilmington, DE, USA; ² Merck Research Laboratories, Blue Bell, PA, USA; ³ Merck & Co., Inc, West Point, PA, USA
PCV49	ADVANTAGES AND LIMITATIONS OF USING A WEB-BASED SURVEY TO OBTAIN PATIENT-REPORTED OUTCOMES Chen KS¹, Plauschinat CA², Frech F², Dubois RW¹, Doan Q¹ ¹ Cerner Health Insights, Beverly Hills, CA, USA; ² Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

CARDIOVASCULAR DISEASE-Myocardial Infarction

PCV50	VENOUS THROMBOEMBOLISM PROPHYLAXIS AND DRUG USE VALUE OF ENOXAPARIN IN HOSPITALIZED MYOCARDIAL INFARCTION PATIENTS Balu S¹, Vogenberg FR², Lichtig L³, O'Connor P³ ¹ Purdue University, West Lafayette, IN, USA; ² Aon Consulting Life Sciences Practice, Providence, RI, USA; ³ Aon Consulting Life Sciences Practice, Wellesley, MA, USA
PCV51	SHORT AND LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDROGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION: A CANADIAN ECONOMIC ANALYSIS Kolm P¹, Veledar E¹, Forte L², Amin M³, Bouin O⁴, Jackson J⁵, Gabriel S⁴, Weintraub WS¹ ¹ Emory University, Atlanta, GA, USA; ² Sanofi-Synthelabo, Markham, ON, Canada; ³ Bristol-Myers Squibb, St Laurent, QC, Canada; ⁴ Sanofi-Aventis, Bagneux, France; ⁵ Bristol-Myers Squibb Company, Princeton, NJ, USA
PCV52	A MULTI-COUNTRY HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI Lamotte M¹, Annemans L¹, Oelze R² ¹ IMS Health, Brussels, Brussels, Belgium; ² Solvay Pharmaceuticals, Hannover, Germany
PCV53	COST ANALYSIS ON ANTICOAGULANT DRUG MARKET He J¹, Griffin B¹, Mahoney A¹, Young J², Burleigh E¹ ¹ Solucient, Berkeley Heights, NJ, USA; ² Solucient, Ann Arbor, MI, USA
PCV54	ECONOMIC AND HUMANISTIC BURDEN OF POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE IN GERMANY Brüggenjürgen BH¹, Reinhold T¹, Lenz C², Mundhenke M², Willich SN¹ ¹ University of Berlin, Berlin, Germany; ² Pfizer Pharma GmbH, Karlsruhe, Germany

CARDIOVASCULAR DISEASE-Other

PCV55	PREVALENCE OF METABOLIC SYMDROME IN KOREAN AMERICANS IN THE UNITED STATES Lee J¹, Chung YH¹, Mak M², Kim K², Wong SL³ ¹ Korean American Physician Organization, New York, NY, USA; ² Oxford Health Plans, New York, NY, USA; ³ Pfizer Inc, Syosset, NY, USA
PCV56	EVALUATION AND COMPARISON OF DIFFERENT MODELS OF METABOLIC SYNDROME USING CONFIRMATORY FACTOR ANALYSIS Shah S¹, Novak S¹, Shepherd M² ¹ University of Texas at Austin, Austin, TX, USA; ² University of Texas, Austin, TX, USA

CARDIOVASCULAR DISEASE-Thrombosis Including DVT

PCV57	COST OF MAJOR BLEEDING FOLLOWING MAJOR ORTHOPEDIC SURGERY Vera-Llonch M, Hagiwara M, Oster G Policy Analysis, Inc (PAI), Brookline, MA, USA
PCV58	CLINICAL AND ECONOMIC ISSUES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED ORTHOPEDIC PATIENTS: ENOXAPARIN VERSUS WARFARIN Balu S¹, Vogenberg FR², Lichtig L², O'Connor P² ¹ Purdue University, West Lafayette, IN, USA; ² Aon Consulting Life Sciences Practice, Wellesley, MA, USA

ENDOCRINE DISORDERS

PEN1	COST SAVINGS ASSOCIATED WITH FINER DOSING INCREMENTS THROUGH THE USE OF NORDITROPIN NORDIFLEX® IN THE UNITED STATES Joshi AV¹, Gore T¹, Russell MW² ¹ Novo Nordisk Inc, Princeton, NJ, USA; ² Boston Health Economics, Inc, Waltham, MA, USA
PEN2	COST-UTILITY OF NORDITROPIN® (R-DNA SOMATROPIN) IN CHILDREN WITH GROWTH HORMONE DEFICIENCY Joshi AV¹, Nicklasson L¹, Russell MW² ¹ Novo Nordisk Inc, Princeton, NJ, USA; ² Boston Health Economics, Inc, Waltham, MA, USA
PEN3	HEALTH STATUS VALUES (UTILITIES) FOR THE SWEDISH POPULATION: A MODEL BASED ON THE EQ-5D ASSESSMENT OF ACTUAL HEALTH STATE, USING JACKKNIFE METHOD AND MULTIPLE REGRESSION ANALYSIS Jonsson B¹, Koltowska-Haggstrom M², Isacson D³, Bingefors K(³ ¹ Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; ² Pfizer Health AB, Stockholm, Sweden; ³ Department of Pharmacy, Uppsala University, Uppsala, Sweden
PEN4	GENERIC AND DISEASE - SENSITIVE INSTRUMENTS SEEM TO MEASURE QUALITY OF LIFE IN A SIMILAR WAY: RESULTS OF THE EQ-5D AND QOL-AGHDA SURVEY IN THE SWEDISH POPULATION Koltowska-Haggstrom M¹, Jonsson B², Isacson D³, Bingefors K(³ ¹ Pfizer Health AB, Stockholm, Sweden; ² Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; ³ Department of Pharmacy, Uppsala University, Uppsala, Sweden
PEN5	ESTIMATING THE QUALITY OF LIFE DEFICIT IN ADULT GROWTH HORMONE DEFICIENCY USING AN EQ-5D CALIBRATED INDEX Kind P¹, Koltowska-Haggstrom M² ¹ University of York, York, United Kingdom; ² University of Uppsala, Uppsala, Sweden
PEN6	EVALUATION OF THE ASSOCIATION BETWEEN HEIGHT AND HEALTH-RELATED UTILITY (EQ5D_INDEX) Woehl A¹, Davies S², Scanlon MF², Currie CJ² ¹ Kiel University, Kiel, Germany; ² Cardiff University School of Medicine, Cardiff, United Kingdom

HEMATOLOGICAL DISORDERS

PHM1	EFFECTIVENESS OF EPOETIN ALFA IN REDUCING THE NUMBER OF BLOOD TRANSFUSIONS IN CRITICALLY ILL SICU PATIENTS Luh VW¹, Barlev A², Kern J³ ¹ City of Hope National Medical Center, Duarte, CA, USA; ² Covance, San Diego, CA, USA; ³ University of Southern California, Los Angeles, CA, USA
PHM2	IMPACT OF ANEMIA ON IN-HOSPITAL FALLS: A MATCHED CASE-CONTROL STUDY Mallik AV¹, Coley KC¹, Kirisci L¹, Painter L² ¹ University of Pittsburgh, Pittsburgh, PA, USA; ² University of Pittsburgh Medical Center, Pittsburgh, PA, USA
PHM3	DOES ANEMIA CONTRIBUTE TO LONGER LENGTH OF STAY IN PATIENTS WITH IN-HOSPITAL FALLS? Mallik AV¹, Coley KC¹, Kirisci L¹, Painter L² ¹ University of Pittsburgh, Pittsburgh, PA, USA; ² University of Pittsburgh Medical Center, Pittsburgh, PA, USA
PHM4	COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN CHINA Staginnus U¹, Russell S² ¹ Premor Associates, New York, NY, USA; ² Premor Associates, Madrid, Spain
PHM5	RECOMBINANT HUMAN FACTOR VII USE: AN EVALUATION OF PATIENT CHARACTERISTICS AND OUTCOMES FROM AN ELECTRONIC DATABASE OF ACADEMIC HEALTH CENTERS Magnetti S, Oinonen M, Matuszewski K University HealthSystem Consortium, Oak Brook, IL, USA
PHM6	A HIDDEN EPIDEMIC AMONG ACUTE CARE INPATIENTS: ECONOMIC AND CLINICAL IMPACTS OF ANEMIA IN SELECTED CHRONIC DISEASES Wang PF, Saunders W, Gaylord B, Vardireddy N Premier Health Informatics, Charlotte, NC, USA

HEALTH POLICY

PHP1	COST EFFECTIVENESS OF INTERVENTIONS TO IMPROVE ADHERENCE: WHAT IS THE QUALITY OF THE EVIDENCE? Elliott RA¹, Barber N², Horne R³ ¹ Harvard University, Boston, MA, USA; ² University of London, London, United Kingdom; ³ University of Brighton, Brighton, Sussex, United Kingdom
PHP2	THE MEDINET-PROJECT - A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS. Sterz R¹, Lebmeier M², Simon U³ ¹ Abbott GmbH & Co. KG, Ludwigshafen, Rhineland-Palati, Germany; ² Sheffield University, Sheffield, United Kingdom; ³ ES-Q-Lab, Lauf, Bavaria, Germany
PHP3	IMPACT OF INCREASED COPAYMENTS ON THE SWITCHING AND DISCONTINUATION RATES FOR NON FORMULARY MEDICATIONS Nair KV¹, Valuck RJ² ¹ University of Colorado Health Sciences Center, Denver, CO, USA; ² University of Colorado, Denver, CO, USA
PHP4	IMPACT OF COST ON MEDICATION COMPLIANCE IN PATIENTS WITH DIFFERENT LEVELS OF PERCEIVED BENEFITS Fuldeore M¹, Krueger KP², Lee K¹, Berger BA², Bertram C¹, Shannon D², Ekelund R² ¹ Walgreens Health Initiatives, Deerfield, IL, USA; ² Auburn University, Auburn, AL, USA
PHP5	TOOLS TO INCREASE THE APPROPRIATENESS OF ALBUMIN UTILIZATION IN AN ITALIAN COMMUNITY HOSPITAL Panella M¹, Marchisio S², Barbieri A², Broglio E³ ¹ University of Eastern Piedmont, Novara, Italy; ² Saint Andrew Hospital, Vercelli, Italy; ³ Saint Andrew's Hospital, Vercelli, Italy
PHP6	SUMMARIZING DRUG USE OVER TIME: THE DRUG-O-GRAM Gause D, Plauschinat CA Novartis Pharmaceuticals, East Hanover, NJ, USA
PHP7	PRESCRIPTION DRUG NONCOMPLIANCE AMONG TRICARE BENEFICIARIES AT MILITARY PHARMACIES Esposito D¹, Schone E², Williams T³, CyBulski K¹, Stapulonis R¹, Clusen N², Nolan E⁴ ¹ Mathematica Policy Research, Inc, Princeton, NJ, USA; ² Mathematica Policy Research, Inc, Washington, DC, USA; ³ TRICARE Management Authority, Falls Church, VA, USA; ⁴ US Navy Pharmacy Board, Falls Church, VA, USA
PHP8	EVALUATION OF A CLINICAL PHARMACOKINETIC MONITORING SYSTEM Chan YY¹, Tsai CY¹, Tarn YH², Tseng HM³ ¹ Chang Gung Memorial Hospital, Taoyuen Hsien, Taiwan; ² Taipei City Hospital, Taipei, Taipei, Taiwan; ³ Chang Gung University, Taoyuen Hsien, Taiwan
PHP9	EVALUATION OF A PLAN-PARTICIPANT MAILING PROGRAM TO ENCOURAGE USE OF MAIL-SERVICE PHARMACY AND FORMULARY DRUGS Powers CA¹, Parsons O², Meyer CM¹, Marks AS² ¹ Caremark Inc, Hunt Valley, MD, USA; ² Caremark Inc, Northbrook, IL, USA
PHP10	UTILIZATION AND COSTS OF A 90-DAY RETAIL PROGRAM IN COMPARISON WITH 30-DAY RETAIL AND MAIL SERVICES Lee K, Sun SX, Kleyn L, McMurray J, Zagorski B, Bertram C Walgreens Health Initiatives, Deerfield, IL, USA
PHP11	IMPACT OF A 90-DAY RETAIL PROGRAM ON PRESCRIPTION DRUG EXPENDITURES Sun SX, Lee K, Kleyn L, McMurray J, Fuldeore M, Bertram C Walgreens Health Initiatives, Deerfield, IL, USA
PHP12	SOCIAL AND ECONOMIC FACTORS AFFECTING INTENTIONAL PRESCRIPTION DRUG NON-COMPLIANCE AMONG NOVA SCOTIA SENIORS Okihiro NR, Davis N, MacRae H Mount St. Vincent University, Halifax, NS, Canada
PHP13	TRENDS IN THE PREVALENCE OF INAPPROPRIATE PRESCRIBING AMONG ELDERLY MEDICARE BENEFICIARIES, 1992-2001 Mahmood M¹, Craig BM¹, Ko Y¹, Armstrong EP² ¹ University of Arizona, Tucson, AZ, USA; ² University of Arizona College of Pharmacy, Tucson, AZ, USA
PHP14	MAKING A CASE FOR EMPLOYING SOCIETAL PERSPECTIVE IN THE EVALUATION OF MEDICAID FORMULARIES Roy S, Madhavan SS West Virginia University, Morgantown, WV, USA
PHP15	PHARMACOECONOMIC EDUCATION AT MEDICAL SCHOOLS IN TURKEY Tulunay F, Gulmez S, Ergun H Ankara University School of Medicine, Ankara, Turkey
PHP16	ADVERTISING IN RESPONSE TO NEW PRODUCT ENTRY: AN EXAMINATION OF THE STRATEGIC ROLE OF PHARMACEUTICAL ADVERTISING ON MARKET COMPETITION Kwong WJ¹, Norton EC² ¹ GlaxoSmithKline Research and Development, Research Triangle Park, NC, USA; ² The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
PHP17	MODELING THE COST AND UTILIZATION OF MAIL ORDER VS. COMMUNITY PHARMACY IN A MEDICAID POPULATION Valluri SC, Rodriguez-Monguio R, Seoane-Vazquez EC Ohio State University, Columbus, OH, USA
PHP18	THE INFLUENCE OF DRUG COPAY CHANGE ON DRUG UTILIZATION: THE CASE OF SMALL-FIRM EMPLOYEES IN CALIFORNIA Thiebaud P, Nichol MB University of Southern California, Los Angeles, CA, USA
PHP19	MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE Tran BV¹, Mullins CD², Shaya FT¹, McNally D¹, McEwan RN³ ¹ University of Maryland, Baltimore, MD, USA; ² Pharmaceutical Health Services Research, Baltimore, MD, USA; ³ MEDBANK of Maryland, Inc, Towson, MD, USA
PHP20	EFFECT OF A PHARMACY BENEFIT CHANGE ON ACCURACY OF PRESCRIPTION DATABASE’S DAYS SUPPLY VARIABLE Smith K¹, Smith D², Hazlet TK³, Malone DC¹ ¹ University of Arizona College of Pharmacy, Tucson, AZ, USA; ² Center for Health Research, Kaiser Permanente NW, Portland, OR, USA; ³ University of Washington, Seattle, WA, USA
PHP21	TRENDS IN PHARMACEUTICAL SPENDING GROWTH IN THE UNITED STATES, 1998-2002 Roberts WM, Rindress D BioMedCom Consultants, inc, Montréal, QC, Canada
PHP22	IMPACT OF HEALTH INSURANCE ON HEALTH-RELATED QUALITY OF LIFE Bharmal M, Thomas III J Purdue University, West Lafayette, IN, USA
PHP23	WITHDRAWN
PHP24	THE DETERMINANTS OF EXPENDITURES ON PHARMACEUTICALS AND OTHER MEDICAL NON-DURABLES IN OECD COUNTRIES Zhang D¹, Carlson A² ¹ University of Minnesota, Minneapolis, MN, USA; ² Data Intelligence, Eden Prairie, MN, USA
PHP25	ANALYSIS OF PRESCRIBING PATTERN WITH THE NEGATIVE LIST FORMULARY SYSTEM IN KOREA Lee EK, Park EJ Korea Institute for Health and Social Affairs, Seoul, SEOUL, South Korea
PHP26	THE CURRENT AND FUTURE OF PHARMACOECONOMICS IN UKRAINE Zaliska OM, Parnovsky B Lviv National Medical University named Danylo Galitsky, Lviv, Ukraine
PHP27	QUALITY OF ECONOMIC MODELS IN DOSSIERS SUBMITTED UNDER THE AMCP FORMAT Colmenero F¹, Sullivan S², Watkins J³, Neumann P⁴ ¹ Harvard School of Public Health, Boston, MA, USA; ² University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA; ³ Premera Blue Cross, Mountlake Terrace, WA, USA; ⁴ Harvard University, Boston, MA, USA
PHP28	THE EFFECT OF CORPORATE STRUCTURE ON FORMULARY DESIGN: THE CASE OF LARGE INSURANCE COMPANIES Abrams L Nu-Retail, Watsonville, CA, USA
PHP29	AN ANALYSIS OF PUBLICATION RATES OF ABSTRACTS PRESENTED AT THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) INTERNATIONAL AND EUROPEAN CONFERENCES DURING YEARS 2000 THROUGH 2003 Vo PG¹, Nichol MB², Borok GM³ ¹ University of Southern California, Los Angeles, CA, USA; ² University of Southern California, School of Pharmacy, Los Angeles, CA, USA; ³ AstraZeneca, Encino, CA, USA
PHP30	USE OF EMERGENCY DEPARTMENTS BY HOMELESS PERSONS FOR NON-EMERGENCY CARE DURING ONE YEAR: RESOURCE USE AND COST O'Brien JA¹, Pitoniak-Morse C¹, Jacobs LM² ¹ Caro Research Institute, Concord, MA, USA; ² University of Connecticut Medical School, Farmington, CT, USA
PHP31	SAFETY NET ACTIVITIES STRUCTURAL CHARACTERISTICS & MEMBERSHIP IN LOCAL HOSPITAL SYSTEMS Khan N University of Illinois at Chicago, Chicago, IL, USA
PHP32	TRENDS AND OUTCOMES ASSOCIATE WITH DTCA PRINT SUMMARY FORMATS: A FOUR YEAR STUDY OF PRINT ADS Sansgiry SS¹, Kawatkar AA¹, Chanda S¹, Jayawant S², Sail K¹ ¹ University of Houston, Houston, TX, USA; ² University of Houston College of Pharmacy, Houston, TX, USA
PHP33	UTILITY OF MEDIA ON HEALTH PROMOTION AND SELFMEDICATION Tasic D¹, Mladenovska D², Tasic L¹ ¹ Faculty of Pharmacy, Belgrade University, Belgrade, Serbia and Montenegro; ² Public Health Center Vrsac, Vrsac, Serbia and Montenegro
PHP34	AN ASSESSMENT OF THE ASSOCIATION BETWEEN UNDERLYING WORKER MEDICAL CONDITIONS AND WORKER ABSENTEEISM IN THE US Mavros P¹, Pietri G² ¹ Merck & Co., Inc, Whitehouse Station, NJ, USA; ² Rutgers University, Piscataway, NJ, USA
PHP35	OUTCOMES OF TECHNOLOGY APPLICATION ON PHARMACISTS JOB PERFORMANCE: THE ROLE OF PERSONAL DIGITAL ASSISTANTS Sikri S, Sansgiry SS University of Houston, Houston, TX, USA
PHP36	EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE PHARMACEUTICAL BENEFITS BOARD IN SWEDEN. – DATA FROM THE FIRST TWO YEARS Odeberg S, Engstrom A, Jacob J, Lundin D, Ramsberg J Pharmaceutical Benefits Board, Solna, Sweden
PHP37	EVALUATING PHARMACEUTICALS FOR REIMBURSEMENT IN KOREA Choi SE¹, Sullivan SD² ¹ Health Insurance Review Agency, Seoul, South Korea; ² University of Washington, Seattle, WA, USA
PHP38	A CENTRAL COMPUTERIZED DRUG PRIOR-AUTHORIZATION PROCESS IN A MANAGED CARE SETTING IN ISRAEL Kahan NR, Blackman S, Brami JL, Waitman DA Leumit Health Fund (HMO), Tel-Aviv, Israel
PHP39	DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A COMMERCIAL POPULATION Cantrell CR¹, Martin BC² ¹ GlaxoSmithKline, Research Triangle Park, NC, USA; ² University of Arkansas for Medical Sciences, Little Rock, AR, USA
PHP40	DEVELOPING KEY PERFORMANCE INDICATORS FOR THE AUSTRALIAN REIMBURSEMENT SYSTEM Abela M¹, Davey P¹, Carroll J¹, Brown B², Yates R¹ ¹ Medical Technology Assessment Group Pty Ltd, Sydney, NSW, Australia; ² Medical Technology Assessment Group Ltd, London, London, United Kingdom
PHP41	A PRELIMINARY ANALYSIS OF THE RELATIONSHIP BETWEEN CONSULTATION LENGTH AND PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE Richard LJ¹, Lister SP² ¹ Heron Evidence Development, Letchworth Garden City, United Kingdom; ² CompuFile Ltd, Woking, Surrey, United Kingdom
PHP42	AN EXPLORATION OF PATIENT FACTORS INFLUENCING PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE Richard LJ¹, Lister SP² ¹ Heron Evidence Development, Letchworth Garden City, United Kingdom; ² CompuFile Ltd, Woking, Surrey, United Kingdom
PHP43	FACTORS THAT INFLUENCE PRESCRIBING OF LOW-MOLECULAR-WEIGHT HEPARINS Blackburn J¹, Walton SM¹, Nutescu EA¹, Park H¹, Schumock G¹, Lewis R², Finley JM³ ¹ University of Illinois at Chicago, Chicago, IL, USA; ² ProCe Inc, Bartlett, IL, USA; ³ Broadlane, Dallas, TX, USA
PHP44	USING THE TRANSTHEORETICAL MODEL (TTM) TO EXPLAIN, PREDICT OR INFLUENCE PHYSICIAN PATIENT CARE BEHAVIOR: A SYSTEMATIC REVIEW Roy AN, Kavookjian J West Virginia University, Morgantown, WV, USA
PHP45	EVALUATING THE EFFECTIVENESS OF A PROTOCOL FOR SEDATION OF MECHANICALLY VENTILATED PATIENTS IN AN ACUTE CARE SETTING Basskin LE North Shore Medical Center, Cooper City, FL, USA
PHP46	IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION Blackburn J¹, Schumock G¹, Nutescu EA¹, Walton SM¹, Finley JM², Lewis R³ ¹ University of Illinois at Chicago, Chicago, IL, USA; ² Broadlane, Dallas, TX, USA; ³ ProCe Inc, Bartlett, IL, USA
PHP47	COST-MINIMIZATION ANALYSIS OF SEROLOGIC SCREENING POLICY OPTIONS FOR US ARMY ACCESSION IMMUNIZATIONS Nevin RL¹, Niebuhr DW¹, Frick KD² ¹ Walter Reed Army Institute of Research, Silver Spring, MD, USA; ² Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
PHP48	ISPOR PHARMACOECONOMICS & OUTCOMES RESEARCH ABSTRACTS: TRENDS & QUALITY INDICATORS Dix Smith M¹, McGhan WF² ¹ ISPOR, Lawrenceville, NJ, USA; ² University of the Sciences, Philadelphia, PA, USA
PHP49	BRIEF SUMMARY FORMATS OF DTCA TO IMPROVE CONSUMER COMPREHENSION Sansgiry SS, Kawatkar AA University of Houston, Houston, TX, USA

HEALTH–Children’s

PIH1	INCORPORATING OF HERD IMMUNITY INTO PHARMACOECONOMIC EVALUATION OF PNEUMOCOCCAL CONJUGATE VACCINE PNC-7 Claes C¹, Reinert RR², Schulenburg JM¹ ¹ University of Hanover, Hannover, Germany; ² Institute for Medical Microbiology, Aachen, Germany
PIH2	THE COST-EFFECTIVENESS OF EXPANDING NEWBORN SCREENING FOR INHERITED METABOLIC DISORDERS USING TANDEM MASS SPECTROMETRY Cipriano LE, Rupar CA, Zaric GS University of Western Ontario, London, ON, Canada
PIH3	DIRECT COST OF TREATMENT FOR AUTISM SPECTRUM DISORDER IN CALIFORNIA MEDICAID Flanders S¹, Engelhart L² ¹ Janssen Medical Affairs, Grayslake, IL, USA; ² Janssen Medical Affairs, Titusville, NJ, USA
PIH4	THE QUALITY OF COMMUNITY PEDIATRICIAN'S PRESCRIPTIONS Triki N, Cohen R, Raz M Maccabi Healthcare Services, Rishon Le Zion, Israel
PIH5	USE OF ANTIBIOTICS IN ASSOCIATION WITH DIAGNOSES OF UPPER RESPIRATORY INFECTIONS IN A LARGE ISRAELI HMO Silverman BG, Hemo B, Friedman N Maccabi Healthcare Services, Tel Aviv, Israel
PIH6	TESTING FOR STREPTOCOCCAL INFECTIONS IN CHILDREN WITH PHARYNGITIS TREATED WITH ANTIBIOTICS IN A LARGE ISRAELI HMO, 2003 Silverman BG, Hemo B, Friedman N Maccabi Healthcare Services, Tel Aviv, Israel

HEALTH–Elderly

PIH7	THE PREVALENCE OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE ELDERLY Jiang JZ¹, Fu AZ², Perri M¹ ¹ University of Georgia, Athens, GA, USA; ² University of North Carolina, Chapel Hill, NC, USA
PIH8	INAPPROPRIATE PRESCRIBING FOR ELDERLY PATIENTS IN TWO OUTPATIENT SETTINGS Poston S, Liu-Chen X, Maio V, Hartmann CW, Arenson C, Diamond JJ Jefferson Medical College, Philadelphia, PA, USA
PIH9	MORAL HAZARD AND PRESCRIPTION DRUG USE AMONG NON-INSTITUTIONALIZED ELDERLY MEDICARE BENEFICIARIES Gajria KL¹, Pyles MA² ¹ QualityMetric Inc, Lincoln, RI, USA; ² Viginia Commonwealth University, Richmond, VA, USA
PIH10	AN EXAMINATION OF SELF-REPORTED CHRONIC CONDITIONS AND HEALTH STATUS IN THE 2001 MEDICARE HEALTH OUTCOMES SURVEY Ko Y, Coons SJ University of Arizona, Tucson, AZ, USA
PIH11	THE EFFECT OF OVER-THE-COUNTER DRUG MISUSE AND THE ASSOCIATED ADES ON HRQOL IN THE ELDERLY Sansgiry SS, Nadkarni A, Chanda S University of Houston, Houston, TX, USA
PIH12	RELATIONSHIP BETWEEN QUALITY OF LIFE AND INAPPROPRIATE DRUG USE: A RETROSPECTIVE ANALYSIS IN AN ELDERLY POPULATION Jiang JZ, Franic D University of Georgia, Athens, GA, USA

HEALTH–Men’s

PIH13	COST-EFFECTIVENESS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENTS DiSantostefano R, Biddle A, Lavelle J University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
PIH14	USE OF SILDENAFIL CITRATE IN NON-ADHERENT PATIENTS WITH CVD, DIABETES OR DEPRESSION McLaughlin T¹, Harnett J², Scott B³, Burhani S¹ ¹ NDCHealth, Phoenix, AZ, USA; ² Pfizer Inc, New York, NY, USA; ³ NDCHealth, Westerville, OH, USA
PIH15	IMPACT OF BENEFIT DESIGN ON PDE-5 UTILIZATION AND COSTS IN A LARGE PBM DATABASE Patel BV¹, Leslie RS¹, Harnett J², Szczotka A¹ ¹ MedImpact Healthcare Systems, Inc, San Diego, CA, USA; ² Pfizer Inc, New York, NY, USA
PIH16	UTILIZATION PATTERNS OF SIDENAFIL CITRATE IN A SENIOR MANAGED CARE POPULATION Harnett J¹, Broderick WC² ¹ Pfizer Inc, New York, NY, USA; ² Ingenix, Houston, TX, USA
PIH17	EVALUATION OF TADALAFIL AND VARDENAFIL TREATMENT PATTERNS IN PRIOR SILDENAFIL USERS Harnett J¹, McLaughlin T², Burhani S², Scott B³ ¹ Pfizer Inc, New York, NY, USA; ² NDC Health, Phoenix, AZ, USA; ³ NDCHealth, Westerville, OH, USA
PIH18	DIRECT COSTS OF ERECTILE DYSFUNCTION IN A MANAGED CARE SETTING--EVIDENCE FROM A LARGE NATIONAL CLAIMS DATABASE Sun P¹, Seftel A², Swindle R¹, Ye W¹, Pohl G¹ ¹ Lilly Research Laboratories, Indianapolis, IN, USA; ² Case Western University, School of Medicine, Cleveland, OH, USA

HEALTH–Women’s

PIH19	COST-EFFECTIVENESS OF PHARMACIST PRESCRIBING AUTHORITY FOR EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA Soon JA¹, Meckley LM², Levine M¹, Fielding D¹, Ensom MHH¹, Marciante KD³ ¹ University of British Columbia, Vancouver, BC, Canada; ² University of Washington, Seattle, WA, USA; ³ Artis LLC, Tacoma, WA, USA
PIH20	COST OF ILLNESS STUDY OF NAUSEA AND VOMITING OF PREGNANCY IN CANADA Piwko C¹, Ungar WJ¹, Einarson TR², Koren G¹ ¹ The Hospital for Sick Children, Toronto, ON, Canada; ² University of Toronto, Toronto, ON, Canada
PIH21	ADJUSTMENT FOR PUBLICATION BIAS CHANGES THE APPARENT EFFICACY OF HORMONE TREATMENT- UNADJUSTED DATA MIGHT DISTORT THE RISK –BENEFIT TRADE OFF Badamgarav E¹, Borenstein J², Song PJ¹, Dubois RW¹ ¹ Cerner Health Insights, Beverly Hills, CA, USA; ² Cedars-Sinai Health System, Los Angeles, CA, USA
PIH22	NEW INSIGHTS INTO THE PLACEBO EFFECTS: A CASE STUDY OF THE EFFECTIVENESS OF HORMONE THERAPY ON THE FREQUENCY OF HOT FLASHES Song PJ¹, Badamgarav E¹, Dubois RW¹, Borenstein J² ¹ Cerner Health Insights, Beverly Hills, CA, USA; ² Cedars-Sinai Health System, Los Angeles, CA, USA
PIH23	HEALTH PREFERENCES AND WILLINGNESS TO PAY TO REDUCE EXPOSURE TO POST-MENOPAUSAL RISK FACTORS Szeinbach SL¹, Harpe SE², Fouad M³, Ohsfeldt RL⁴ ¹ Ohio State University, Columbus, OH, USA; ² Virginia Commonwealth University, Richmond, VA, USA; ³ University of Alabama at Birmingham, Birmingham, AL, USA; ⁴ The University of Iowa College of Public Health, Iowa City VAMC, IA, USA

INFECTION

PIN1	OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS: TREATMENT AND OUTCOMES Singer ME¹, Asche CV², Rose J¹ ¹ Case School of Medicine, Cleveland, OH, USA; ² University of Utah, Salt Lake City, UT, USA
PIN2	EFFECT OF INAPPROPRIATE ANTIBIOTIC THERAPY ON CLINICAL OUTCOMES OF PATIENTS WITH PSEUDOMONAS AERUGINOSA BACTEREMIA Rao B, Tam V, Garey KW University of Houston, College of Pharmacy, Houston, TX, USA
PIN3	DURATION OF ANTIBIOTIC TREATMENT IN HOSPITALIZED PATIENTS WITH COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI): FINDINGS FROM A CLINICAL STUDY COMPARING TIGECYCLINE AND VANCOMYCIN/AZTREONAM Yu H¹, Mallick R¹, Weber DJ² ¹ Wyeth Research, Collegeville, PA, USA; ² University of North Carolina, Chapel Hill, NC, USA
PIN4	IMPACT OF EMPIRIC ANTIFUNGAL THERAPY ON MORTALITY IN HOSPITALIZED PATIENTS WITH BLOODSTREAM CANDIDEMIA Rege M¹, Garey KW¹, Gentry L² ¹ University of Houston, College of Pharmacy, Houston, TX, USA; ² St. Luke's Episcopal Hospital, Houston, TX, USA
PIN5	COST ANALYSIS OF A FEBRILE NEUTROPENIA ALGORITHM WITH RESPECT TO EMPIRICAL ANTIFUNGAL THERAPY IN ADULT HEMATOLOGY/ONCOLOGY PATIENTS Collins CD, DePestel DD, Stuntebeck ER, Shehab N, Erba HP, Stevenson JG The University of Michigan Health System, Ann Arbor, MI, USA
PIN6	ECONOMIC EVALUATION OF VACCINATION AGAINST STREPTOCOCCUS PNEUMONIAE IN GERMANY INCLUDING HERD IMMUNITY EFFECTS Reinert RR¹, Lloyd A², Scott DA², Patel N², Runge C³ ¹ University Hospital, Aachen, Germany; ² Fourth Hurdle Consulting Ltd, London, United Kingdom; ³ Wyeth Pharma GmbH, Muenster, Germany
PIN7	AN UPDATED EVALUATION OF THE COST-EFFECTIVENESS OF VACCINATING ADOLESCENTS FOR PERTUSSIS Getsios D¹, Caro JJ², El-Hadi W³, Payne K³, O'Brien J² ¹ Caro Research Institute, Hammonds Plains, NS, Canada; ² Caro Research Institute, Concord, MA, USA; ³ Caro Research Institute, Dorval, QC, Canada
PIN8	ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN KOREA Moeremans K¹, Annemans L², Ryu JS³, Choe KW⁴, Shin WS⁵ ¹ HEDM, Brussels, Belgium; ² IMS Health, Brussels, Brussels, Belgium; ³ University of Ulsan College of Medicine, Seoul, South Korea; ⁴ Seoul National University College of Medicine, Seoul, South Korea; ⁵ Catholic University of Korea, St Mary's Hospital, Seoul, South Korea
PIN9	EXPLORING THE COST-EFFECTIVENESS OF AN IMMUNISATION PROGRAMME FOR ROTAVIRUS GASTROENTERITIS IN THE UNITED KINGDOM Lorgelly PK¹, Joshi D¹, Iturriza Gómara M², Gray J², Mugford M¹ ¹ University of East Anglia, Norwich, Norfolk, United Kingdom; ² Health Protection Agency, London, London, United Kingdom
PIN10	ECONOMIC ANALYSIS OF VACCINATION WITH MENACTRA IN THE US Getsios D¹, Möller J², Caro JJ², Caro I³, El-Hadi W³, O'Brien J², Chevat C⁴, Coudeville L⁴, Nguyen VH⁴ ¹ Caro Research Institute, Hammonds Plains, NS, Canada; ² Caro Research Institute, Concord, MA, USA; ³ Caro Research Institute, Dorval, QC, Canada; ⁴ Aventis Pasteur SA, Lyon Cedex, France
PIN11	A COST – EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CANDIDIASIS AND INVASIVE ASPERGILLOSIS IN MEXICO Mould Quevedo JF, Contreras I, García - Contreras F, Nevarez A, Constantino - Casas P, Garduño J Social Security Mexican Institute, México D.F, México D.F, Mexico
PIN12	INFANTILE GASTROENTERITIS IN THE COMMUNITY: A COST OF ILLNESS STUDY Lorgelly PK¹, Joshi D¹, Iturriza Gómara M², Flood C³, Hughes CA⁴, Dalrymple J⁵, Gray J², Mugford M¹ ¹ University of East Anglia, Norwich, Norfolk, United Kingdom; ² Health Protection Agency, London, London, United Kingdom; ³ City University, London, London, United Kingdom; ⁴ Fakenham Medical Practice, Fakenham, Norfolk, United Kingdom; ⁵ Drayton Surgery, Norwich, Norfolk, United Kingdom
PIN13	ANNUAL COST FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN THE UNITED STATES Rojas EG, Liu LZ Pfizer Global Pharmaceuticals, New York, NY, USA
PIN14	OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS: UTILIZATION AND COST Rose J¹, Asche CV², Singer ME¹ ¹ Case School of Medicine, Cleveland, OH, USA; ² University of Utah, Salt Lake City, UT, USA
PIN15	IMPACT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS ON INPATIENT COSTS FOR AN ACADEMIC MEDICAL CENTER Patel N¹, Goldfarb N¹, Hartmann CW¹, Maio V¹, Horn DL², Pizzi L¹ ¹ Jefferson Medical College, Philadelphia, PA, USA; ² Thomas Jefferson University, Philadelphia, PA, USA
PIN16	COST-UTILITY OF CHRONIC HEPATITIS “C” TREATMENT WITH THYMOSIN ALPHA 1 IN MEXICO Nevárez-Sida A, García-Contreras F, Constantino-Casas P, Castro-Rios A, Mould J, Garduño-Espinosa J Mexican Institute of Social Security, Mexico City, Mexico
PIN17	A COMPARISON OF METHODS TO ASSESS QUALITY OF LIFE IN ECONOMIC ANALYSES OF HEPATITIS C TREATMENTS Yeh WS, Skrepnek GH, Armstrong EP, Malone DC University of Arizona College of Pharmacy, Tucson, AZ, USA
PIN18	ESTIMATES OF HEALTH CARE COSTS FOR LAMIVUDINE- REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS Tafesse E¹, Claxton A², Granger A², Sanders J³, Appelian D¹, Atillasoy E⁴, Iloeje U¹ ¹ Bristol-Myers Squibb, Wallingford, CT, USA; ² RTI-Health Solutions, Research Triangle Park, NC, USA; ³ Harvard University, Brookline, MA, USA; ⁴ Bristol-Myers Squibb, Plainsboro, NJ, USA
PIN19	UTILISATION OF ANTIBIOTICS WITHIN THE SLOVAK REPUBLIC Tesar T¹, Foltan V¹, Tomek D², Visnansky M³ ¹ Comenius University, Bratislava, Slovak Republic; ² Health Insurance fund APOLLO, Bratislava, Slovak Republic; ³ Faculty of Pharmacy, Comenius University, Bratislava, Bratislava, Slovak Republic
PIN20	IMPROVEMENT IN ANTIMALARIAL DRUGS ACCESS: RESULTS OF A PROGRAM PERFORMED IN YAOUNDE N'Do J¹, Perard R², Brun P³ ¹ Cameroon Ministry of Health, Yaoundé, Yaounde, Cameroon; ² Economic University, Marseille, Paris, Paris, France; ³ Sanofi-Aventis, Paris, Paris, France
PIN21	WITHDRAWN
PIN22	HOSPITALIZED COMMUNITY ACQUIRED PNEUMONIA: A THREE YEAR REVIEW OF PATIENT FACTORS ASSOCIATED WITH PROLONGED LENGTH OF STAY DePestel D¹, Dettloff R², Wolfe T³, Townsend K⁴, DeLor B⁵, Giannamore M⁶ ¹ University of Michigan Health System, Ann Arbor, MI, USA; ² Pfizer, Rockford, MI, USA; ³ Pfizer, Westerville, OH, USA; ⁴ Pfizer, Chelsea, MI, USA; ⁵ Pfizer, Hartland, MI, USA; ⁶ Pfizer, Dublin, OH, USA
PIN23	ARE SUBJECTS ENROLLED IN CANDIDEMIA CLINICAL TRIALS REPRESENTATIVE OF MOST HOSPITALIZED PATIENTS WITH THIS DISORDER Sharma R¹, Rege M², Kachroo S², Garey KW² ¹ Baylor University, Houston, TX, USA; ² University of Houston, College of Pharmacy, Houston, TX, USA
PIN24	ACUTE SINUSITIS OUTCOMES AND CHARGES: A COMPARISON OF TWO FLUOROQUINOLONES Keating KN¹, Perfetto EM², Friedman H³ ¹ Bayer Pharmaceuticals, Inc, West Haven, CT, USA; ² The Weinberg Group, Inc, Washington, DC, USA; ³ Analytic Consulting, Manchester, CT, USA
PIN25	CHRONIC RHINOSINUSITIS TREATMENT: A COMPARISON OF MOXIFLOXACIN AND LEVOFLOXACIN TREATMENT DURATION, OUTCOMES, AND CHARGES Perfetto EM¹, Keating KN², Friedman HS³ ¹ The Weinberg Group, Inc, Washington, DC, USA; ² Bayer Pharmaceuticals, Inc, West Haven, CT, USA; ³ Analytic Consulting, Manchester, CT, USA
PIN26	VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR HEPATITIS B PATIENTS IN SINGAPORE Ong SC¹, Lim SG², Li SC¹ ¹ National University Singapore, Singapore, Singapore, Singapore; ² National University Hospital, Singapore, Singapore
PIN27	PROSPECTIVE OBSERVATIONAL STUDY OF PATIENT REPORTED OUTCOMES FOR AZITHROMYCIN VS. USUAL CARE IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATIONS OF CHRONIC BRONCHITIS Milstone AP¹, Feurer I¹, Harnett J², Luke DR² ¹ Vanderbilt University Medical Center, Nashville, TN, USA; ² Pfizer Inc, New York, NY, USA
PIN28	THE COST-EFFECTIVENESS OF PREVENTING MOTHER-TO-CHILD TRANSMISSION OF HIV IN CHINA Zhang H, Zaric GS University of Western Ontario, London, ON, Canada
PIN29	COST OF THERAPY FOR ARV NAIVE HIV-INFECTED PATIENTS: FOSAMPRENAVIR / RITONAVIR VERSUS NELFINAVIR Lee WC¹, Hoffmann M¹, Stephens J¹, Williams K², Liu LZ², Pashos CL³ ¹ Abt Associates, Bethesda, MD, USA; ² Pfizer Global Pharmaceuticals, New York, NY, USA; ³ Abt Associates, Lexington, MA, USA
PIN30	ANEMIA IN HIV/AIDS PATIENTS IN THE HAART ERA: CLINICAL AND HUMANISTIC IMPACT Zilberberg M¹, Mody SH², Ambegaonkar BM³ ¹ Ortho Biotech Clinical Affairs, LLC, Goshen, MA, USA; ² Ortho Biotech Clinical Affairs LLC, Bridgewater, NJ, USA; ³ Consumer Health Sciences International, Princeton, NJ, USA
PIN31	USE OF THE SYMPTOMS DISTRESS MODULE IN AN INTERNATIONAL STUDY Mear I¹, D'Uva F¹, Wu AW², Mollon P³ ¹ Mapi Research Institute, Lyon, Rhône, France; ² Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ³ Pfizer, Kent, Sandwich, United Kingdom

NEUROLOGICAL DISORDERS-Alzheimer’s Disease

PNL1	ASSESSMENT OF COMORBIDITY AND INCIDENCE RATE OF ALZHEIMER’S DISEASE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM Yu YF¹, Yu AP², Lee LJ², Nichol MB³ ¹ HealthCore, Inc, Wilmington, DE, USA; ² University of Southern California, Los Angeles, CA, USA; ³ University of Southern California, School of Pharmacy, Los Angeles, CA, USA
PNL2	THE COST-EFFECTIVENESS OF DONEPEZIL AND RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER’S DISEASE IN THAILAND PRIVATE HOSPITAL Pattanaprateep O, Phongchareonsuk P, Chaikledkaew U Mahidol University, Payathai, Bangkok, Thailand
PNL3	THE COST-EFFECTIVENESS OF QUETIAPINE FOR ALZHEIMER’S DISEASE IN COMMUNITY DWELLING PATIENTS Getsios D¹, Proskorovsky I², Caro JJ³, O'Brien J³, Pesa J⁴, Ward AJ³ ¹ Caro Research Institute, Hammonds Plains, NS, Canada; ² Caro Research Institute, Dorval, QC, Canada; ³ Caro Research Institute, Concord, MA, USA; ⁴ AstraZeneca LP, Wilmington, DE, USA
PNL4	NURSING HOME RESIDENTS WITH ALZHEIMER’S DISEASE: CHANGES IN MANAGEMENT LEVELS AND COSTS OVER A SIX YEAR PERIOD O'Brien J, Duran P, Caro JJ Caro Research Institute, Concord, MA, USA
PNL5	DRUG PERSISTENCY OF TWO CHOLINESTERASE INHIBITORS - RIVASTIGMINE VERSUS DONEPEZIL AMONG ELDERLY PATIENTS WITH ALZHEIMER’S DISEASE Suh DC¹, Thomas S², Valiyeva E¹, Arcona S², Vo L¹ ¹ Rutgers University, Piscataway, NJ, USA; ² Novartis Pharmaceuticals Co, East Hanover, NJ, USA
PNL6	OUTCOMES OF ANTIDEPRESSANT USE IN PATIENTS WITH ALZHEIMER’S DISEASE IN THE CALIFORNIA MEDICAID PROGRAM Yu YF¹, Yu AP², Lee LJ², Nichol MB³ ¹ HealthCore, Inc, Wilmington, DE, USA; ² University of Southern California, Los Angeles, CA, USA; ³ University of Southern California, School of Pharmacy, Los Angeles, CA, USA
PNL7	DIAGNOSING PHYSICIANS, PRESCRIPTION CHOICE AND PATTERNS FOR ALZHEIMER’S DISEASE IN CALIFORNIA MEDICAID PROGRAM Yu AP¹, Lee LJ¹, Yu YF², Nichol MB³ ¹ University of Southern California, Los Angeles, CA, USA; ² HealthCore, Inc, Wilmington, DE, USA; ³ University of Southern California, School of Pharmacy, Los Angeles, CA, USA
PNL8	USING A TOUCHTONE TELEPHONE TO COLLECT DATA FROM ELDERLY CAREGIVERS OF PATIENTS WITH ALZHEIMER’S DISEASE Payne K¹, Lordan ND², Caro JJ², O'Brien J² ¹ Caro Research Institute, Dorval, QC, Canada; ² Caro Research Institute, Concord, MA, USA

NEUROLOGICAL DISORDERS-Epilepsy

PNL9	CARE COSTS OF PARTIAL REFRACTORY EPILEPSY IN MEXICO Castro-Ríos A, Garcia-Contreras F, Nevárez-Sida A, Constantino-Casas P, Carlos-Rivera F, Guzmán-Caniupan J, Contreras-Hernández I, Mould J, Garduño J Mexican Institute of Social Security, Mexico City, Mexico
PNL10	PSYCHOMETRIC EVALUATION OF EPILEPSY-SPECIFIC QUALITY OF LIFE INSTRUMENTS Oyelowo O, Franic D University of Georgia, Athens, GA, USA

NEUROLOGICAL DISORDERS-Migraine

PNL11	AN ECONOMIC EVALUATION OF TRIPTAN PRODUCTS FOR MIGRAINE Perfetto EM¹, Mullins CD², Subedi P², Weis KA³, Healey PJ³ ¹ The Weinberg Group, Inc, Washington, DC, USA; ² University of Maryland School of Pharmacy, Baltimore, MD, USA; ³ Pfizer, Inc, New York, NY, USA
PNL12	TRIPTANS FOR MIGRAINE THERAPY: A COMPARISON BASED ON NUMBER NEEDED TO TREAT AND DOSES NEEDED TO TREAT Mullins CD¹, Weis KA², Perfetto EM³, Subedi P¹, Healey PJ² ¹ University of Maryland School of Pharmacy, Baltimore, MD, USA; ² Pfizer, Inc, New York, NY, USA; ³ The Weinberg Group, Inc, Washington, DC, USA
PNL13	COST-EFFECTIVENESS OF ELETRIPTAN VERSUS ZOLMITRIPTAN: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL Mullins CD¹, Healey PJ², Mychaskiw MA², Meng F¹, Weis KA² ¹ University of Maryland School of Pharmacy, Baltimore, MD, USA; ² Pfizer, Inc, New York, NY, USA
PNL14	IMPACT OF MIGRAINE FREQUENCY ON HEALTH UTILITIES Brown J¹, Neumann P², Papadopoulos G³, Ruoff G⁴, Maizels M⁵, Diamond M⁶, Menzin J¹ ¹ Boston Health Economics, Waltham, MA, USA; ² Harvard University, Boston, MA, USA; ³ Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA; ⁴ Westside Family Medical Center, Kalamazoo, MI, USA; ⁵ Kaiser Permanente, Woodland Hills, CA, USA; ⁶ Diamond Headache Clinic, Chicago, IL, USA
PNL15	FURTHER VALIDATION OF THE MIGRAINE TREATMENT SATISFACTION MEASURE Martin ML¹, Patrick DL², Bushnell DM¹, Gandra SR¹, Pesa J³ ¹ Health Research Associates, Mountlake Terrace, WA, USA; ² University of Washington, Seattle, WA, USA; ³ AstraZeneca LP, Wilmington, DE, USA
PNL16	DEVELOPMENT OF A UNIQUE INTERNET & PHONE BASED SYSTEM TO CAPTURE MIGRAINE TREATMENT OUTCOMES Ambegaonkar AJ, Holdsworth K, Livengood KB, Vlasnik J, Tiseo PJ Pfizer Inc, New York, NY, USA

NEUROLOGICAL DISORDERS-Multiple Sclerosis

PNL17	EFFECT OF IMMUNOMODULATORY THERAPY AND OTHER FACTORS ON PRODUCTIVITY IN MS Lage MJ¹, Castelli-Haley J², Oleen-Burkey M² ¹ HealthMetrics Outcomes Research, Groton, CT, USA; ² Teva Neuroscience, Kansas City, MO, USA
PNL18	THE IMPACT OF MEDICARE PART D ON ECONOMIC BARRIERS TO PRESCRIPTION MEDICATIONS AMONG BENEFICIARIES WITH MULTIPLE SCLEROSIS Lundy JJ, Craig BM University of Arizona, Tucson, AZ, USA
PNL19	DEVELOPMENT OF THE MULTIPLE SCLEROSIS TREATMENT SATISFACTION QUESTIONNAIRE (MSTCQ) Cramer JA¹, Cuffel B² ¹ Yale University, West Haven, CT, USA; ² Pfizer, New York, NY, USA

NEUROLOGICAL DISORDERS-Other

PNL20

RESTLESS LEGS SYNDROME PLACES A SUBSTANTIAL BURDEN ON THE HEALTH-RELATED QUALITY OF LIFE OF US AND EUROPEAN PATIENTS
Martin MC¹, Nikam P², Blaisdell B¹, Kushida CA³, Ferini Strambi L⁴, Ware J¹
¹ Quality Metric Incorporated, Lincoln, RI, USA; ² GlaxoSmithKline, Collegeville, PA, USA; ³ Stanford Center of Excellence for Sleep Disorders, Stanford, CA, USA; ⁴ Università Vita-Salute, Milan, Italy

PNL21

FUNCTIONAL LIMITATIONS, MENTAL HEALTH, AND RESOURCE USE ASSOCIATED WITH THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH RESTLESS LEGS SYNDROME
Martin MC¹, Nikam P², Blaisdell B¹, Kushida CA³, Ferini Strambi L⁴, Ware J¹
¹ Quality Metric Incorporated, Lincoln, RI, USA; ² GlaxoSmithKline, Collegeville, PA, USA; ³ Stanford Center of Excellence for Sleep Disorders, Stanford, CA, USA; ⁴ Università Vita-Salute, Milan, Italy

NEUROLOGICAL DISORDERS-Parkinson’s Disease

PNL22	COST- EFFECTIVENESS OF PRAMIPEXOLE COMPARED WITH PIRIBEDIL IN EARLY PARKINSON’S DISEASE PATIENTS Chikina ES, Gusev EI, Belousov YB, Guecht AB Russian State Medical University, Moscow, Moscow, Russia
PNL23	COST-UTILITY ANALYSIS FOR EARLY PATIENTS WITH PARKINSON’S DISEASE TREATED BY DOPAMINE AGONISTS Chikina ES¹, Belousov YB¹, Gusev EI¹, Belousov DY², Guecht AB¹ ¹ Russian State Medical University, Moscow, Moscow, Russia; ² Russian Society of Clinical Researchers, Moscow, Russia
PNL24	PATTERNS OF RESOURCE USE IN PATIENTS WITH DIFFERENT SEVERITIES OF PARKINSON’S DISEASE Emmermann A¹, Piercy J², Tompkins R², Karavali M² ¹ Schwarz Pharma AG, Monheim, Germany; ² Adelphi Group Products, Bollington, United Kingdom
PNL25	COST AND USE OF PARKINSONISM-INDUCING DRUGS AMONG MEDICARE BENEFICIARIES Noyes K, Liu H, Holloway RG University of Rochester Medical Center, Rochester, NY, USA
PNL26	TREATMENT SATISFACTION AND PRINCIPAL CAUSES OF TERMINATION OF DRUG TREATMENT OF PARKINSON’S DISEASE IN RUSSIA Chikina ES, Gusev EI Russian State Medical University, Moscow, Moscow, Russia

NEUROLOGICAL DISORDERS-Sleep Disorders

PNL27	PREVALENCE OF INSOMNIA AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A LARGE DATABASE Vallarino C, Rajagopalan R, Mini L Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA
PNL28	THE PREVALENCE OF INSOMNIA IN PATIENTS WITH DRUG DEPENDENCY OR ABUSE Xu Y, Iyer S, Mini L Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL, USA
PNL29	COST-EFFECTIVENESS OF LONGER-TERM TREATMENT WITH ESZOPICLONE 3MG IN ADULTS WITH PRIMARY INSOMNIA Botteman M¹, Ozminkowski R², Wang S³, Pashos CL⁴, Foley DJ⁵, Schaefer K⁶ ¹ Abt Associates Inc, Bethesda, MD, USA; ² The Medstat Group (A Thomson Company), Ann Arbor, MI, USA; ³ The Medstat Group (A Thomson Company), Cambridge, MA, USA; ⁴ Abt Associates Inc, Lexington, MA, USA; ⁵ U.S. Substance Abuse and Mental Health Services Administration, Rockville, MD, USA; ⁶ Sepracor Inc, Marlborough, MA, USA
PNL30	FORECASTING THE IMPACT OF ADDING A NEW DRUG ON FORMULARY USING MEDICAL CLAIMS DATA AND CLINICAL LITERATURE: A CASE STUDY OF INSOMNIA TREATMENT Ozminkowski R¹, Lenhart G², Wang S², Barry N³, Schaefer K³, Mucha L², Rubens R³ ¹ The Medstat Group (A Thomson Company), Ann Arbor, MI, USA; ² The Medstat Group (A Thomson Company), Cambridge, MA, USA; ³ Sepracor Inc, Marlborough, MA, USA
PNL31	CLINICAL PRIOR AUTHORIZATION PROGRAM: A STRATEGY FOR CONTROLLING DRUG EXPENDITURES AMONG PATIENTS WITH INSOMNIA Sun SX, McMurray J, Jacobsen V, Fuldeore M, Lee K, Bertram C Walgreens Health Initiatives, Deerfield, IL, USA
PNL32	PHYSICIAN AND PATIENT DETERMINANTS OF THE TREATMENT OF SLEEP DIFFICULTIES IN OUTPATIENT SETTINGS IN THE UNITED STATES Rasu R¹, Balkrishnan R², Rajagopalan R³ ¹ University of Texas Health Science Center, Houston, TX, USA; ² Ohio State University, Columbus, OH, USA; ³ Takeda Pharmaceuticals North America, Lincolnshire, IL, USA
PNL33	SLEEP COMPLAINTS AND DIAGNOSES IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY: 1997-2002 Tan LSM, Morlock R Pifzer Inc, Ann Arbor, MI, USA
PNL34	SEDATIVE HYPNOTICS EMPLOYED TO TREAT PATIENTS WITH AND WITHOUT INSOMNIA COMPLAINTS IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY: 1997-2002 Tan LSM, Morlock R Pifzer Inc, Ann Arbor, MI, USA
PNL35	USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE THE PREVALENCE OF INSOMNIA IN FOUR COUNTRIES Edmondson M, Annunziata K Consumer Health Sciences, Princeton, NJ, USA